Centralized ex vivo lung perfusion technology: this piece previews the device's intended clinical role along with practical evaluation considerations.
Key Takeaways
- FDA granted premarket approval for the centralized ex vivo lung perfusion device
- Device is indicated for centralized evaluation of deceased-donor single and double lungs
- Pivotal CLES trial missed its 12-month survival goal and showed higher mortality